Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28420215 | 0.76 | ALDH1A1 (0.44) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL4070679 | 0.76 | NPSR1 (0.48) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL84561 | 0.74 | ALDH1A1 (0.42) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL24915652 | 0.74 | ALDH1A1 (0.42) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL10254652 | 0.74 | ALDH1A1 (0.47) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL10154731 | 0.72 | ALDH1A1 (0.41) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL6697856 | 0.72 | ALDH1A1 (0.41) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL9911480 | 0.70 | CA1 (0.44) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL8908252 | 0.70 | ALDH1A1 (0.40) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL20348772 | 0.70 | ALDH1A1 (0.40) | ALDH1A1NPSR1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | ALDH1A1 373/4885NPSR1 1173/4885CA1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.